scholarly journals Impact of soluble fms-like tyrosine kinase-1 and placental growth factor serum levels for risk stratification and early diagnosis in patients with suspected acute myocardial infarction

2010 ◽  
Vol 32 (3) ◽  
pp. 326-335 ◽  
Author(s):  
W. Hochholzer ◽  
T. Reichlin ◽  
C. Stelzig ◽  
K. Hochholzer ◽  
J. Meissner ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Growth Factor ◽  
Early Diagnosis ◽  
Risk Stratification ◽  
Tyrosine Kinase ◽  
Serum Levels ◽  
Placental Growth Factor ◽  
Suspected Acute Myocardial Infarction

scholarly journals Maternal Serum Placental Growth Factor, Soluble Fms-Like Tyrosine Kinase-1, and Soluble Endoglin in Twin Gestations and the Risk of Preeclampsia—A Systematic Review

2020 ◽  
Vol 9 (1) ◽  
pp. 183 ◽  
Author(s):  
Katarzyna Kosinska-Kaczynska ◽  
Magdalena Zgliczynska ◽  
Szymon Kozlowski ◽  
Lukasz Wicherek
Keyword(s):  
Growth Factor ◽  
Tyrosine Kinase ◽  
Serum Levels ◽  
Maternal Serum ◽  
Placental Growth Factor ◽  
Cochrane Library ◽  
Original Research ◽  
Multiple Gestation ◽  
Soluble Endoglin ◽  
Twin Pregnancies

Multiple gestation is one of the key risk factors for the occurrence of preeclampsia (PE). Soluble fms-like tyrosine kinase-1, placental growth factor, and soluble endoglin are molecules involved in the process of angiogenesis with a proven role in the pathogenesis of PE. The aim of the review was to summarize available data on maternal serum levels of the above-mentioned factors and their usefulness in predicting PE in twin pregnancies. Only original research articles written in English were considered eligible. Reviews, chapters, case studies, conference papers, experts’ opinions, editorials, and letters were excluded from the analysis. No publication date limitations were imposed. The systematic literature search using PubMed/MEDLINE, Scopus, Embase, and Cochrane Library databases identified 338 articles, 10 of which were included in the final qualitative analyses. The included studies showed significant differences in maternal serum levels of the discussed factors between women with twin pregnancies with PE and those who did not develop PE, and their promising performance in predicting PE, alone or in combination with other factors. The identification of the most effective algorithms, their prompt introduction to the clinical practice, and further assessment of the real-life performance should become a priority.

Serum Levels of Vascular Endothelial Growth Factor in Patients with Acute Myocardial Infarction Undergoing Reperfusion Therapy

1997 ◽  
Vol 92 (5) ◽  
pp. 453-454 ◽  
Author(s):  
Yoshinori Seko ◽  
Yasushi Imai ◽  
Shin Suzuki ◽  
Shuichi Kamijukkoku ◽  
Kazuya Hayasaki ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Serum Levels ◽  
Reperfusion Therapy ◽  
Vascular Endothelial ◽  
Early Reperfusion ◽  
Healthy Control ◽  
Endothelial Growth Factor

1. Vascular endothelial growth factor, a potent angiogenic mitogen, is known to be induced in response to ischaemia as well as being secreted from tumour cells. However, the precise mechanism of vascular endothelial growth factor release in acute myocardial infarction and the effects of coronary reperfusion on the circulating levels of vascular endothelial growth factor are still unknown. 2. Nineteen patients with acute myocardial infarction who underwent early reperfusion therapy were studied. Serum levels of vascular endothelial growth factor before reperfusion were markedly increased as compared with those in 19 healthy control subjects [252.4 ± 158.1 pg/ml (mean ± SD) compared with undetectable]. After reperfusion, the serum vascular endothelial growth factor levels rapidly returned almost completely to the normal control range. 4. These data strongly suggest that the serum level of vascular endothelial growth factor is one of the most sensitive indicators of myocardial ischaemia.

scholarly journals The role of angiogenic factors in preeclampsia

2014 ◽  
Vol 155 (47) ◽  
pp. 1860-1866 ◽  
Author(s):  
Bálint Alasztics ◽  
Nóra Gullai ◽  
Attila Molvarec ◽  
János Rigó Jr.
Keyword(s):  
Growth Factor ◽  
Tyrosine Kinase ◽  
Clinical Symptoms ◽  
Current Knowledge ◽  
Point Of Care ◽  
Serum Levels ◽  
Maternal Blood ◽  
Placental Growth Factor ◽  
Maternal Circulation ◽  
Early Onset Preeclampsia

Preeclampsia is one of the most common and most serious complications of pregnancy and the management of this condition still challenges obstetricians. Despite intensive research the etiology of preeclampsia still remains unclear. At the beginning of the 2000s preeclampsia-related research was directed towards factors that influence angiogenesis. Most studies have been carried out on the placental growth factor and soluble fms-like tyrosine kinase-1. Most publications confirm the increased concentrations of antiangiogenic factors and decreased concentrations of proangiogenic factors in maternal blood samples in preeclampsia even before the onset of clinical symptoms. According to our current knowledge antiangiogenic proteins are responsible for the endothelial dysfunction in the symptomatic stage of the disease. Placental growth factor and soluble fms-like tyrosine kinase-1 may have important roles in the prediction and treatment of the disease. The point of care detection of placental growth factor and soluble fms-like tyrosine kinase-1 may be used to predict preeclampsia. Rapid tests are available to determine the serum levels of the two proteins. Removal of soluble fms-like tyrosine kinase-1 from maternal circulation is a potential treatment option for early onset preeclampsia. Orv. Hetil., 2014, 155(47), 1860–1866.

Serum levels of endostatin, vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in patients with acute myocardial infarction undergoing early reperfusion therapy

2004 ◽  
Vol 106 (5) ◽  
pp. 439-442 ◽  
Author(s):  
Yoshinori SEKO ◽  
Shuichi FUKUDA ◽  
Ryozo NAGAI
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Growth Factor ◽  
Serum Levels ◽  
Reperfusion Therapy ◽  
Vascular Endothelial ◽  
Early Reperfusion ◽  
Ischaemia Reperfusion ◽  
Endothelial Growth Factor ◽  
Hepatocyte Growth

Angiogenesis is controlled by anti-angiogenic factors as well as by angiogenic factors, such as VEGF (vascular endothelial growth factor) and HGF (hepatocyte growth factor). Endostatin, a potent endogenous angiogenesis inhibitor, is known to inhibit endothelial proliferation and suppress tumour growth. However, to date, little is known about the pathophysiology of endostatin in ischaemia/reperfusion. To investigate the mechanisms of angiogenesis induced by myocardial ischaemia/reperfusion in more detail, we studied the circulating levels of endostatin, VEGF and HGF in 17 patients with acute myocardial infarction, who underwent early reperfusion therapy. In all patients, serum endostatin, VEGF and HGF levels before reperfusion were increased significantly compared with those in 17 control subjects (endostatin, 49.2±11.7 ng/ml, but not detectable in controls; VEGF, 685.6±150.3 pg/ml compared with 173.7±33.6 pg/ml; HGF, 3638±1285 pg/ml compared with 59±13 pg/ml; values are means±S.E.M.). After reperfusion, the serum endostatin and VEGF levels decreased significantly, but still remained higher than those in control subjects (endostatin, 19.6±7.0 ng/ml; VEGF, 284.2±90.2 pg/ml). In contrast, serum HGF levels increased significantly (15 146±2230 pg/ml) after reperfusion. These data indicated that serum levels of endostatin changed in parallel with those of VEGF in response to myocardial ischaemia/reperfusion, and the marked increase in serum HGF levels after reperfusion seemed to be, at least in part, due to heparin administration. Our data offer a possible anti-endostatin therapy in patients with acute myocardial infarction to facilitate collateral vessel formation.

Sign in / Sign up

Export Citation Format

Share Document